Condition category
Not Applicable
Date applied
02/12/2014
Date assigned
10/12/2014
Last edited
26/03/2015
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
In the UK it is recommended that adults should aim to undertake at least 150 minutes of moderate to vigorous physical activity (MVPA) throughout the week. Increasing physical activity levels, especially for people who are the least active, is an important aim of current public health policy to help prevent chronic diseases including heart disease, type 2 diabetes, obesity and some cancers. Even walking at a moderate pace (5 km/hour or 3 mph) uses enough energy to meet the definition of MVPA. The aim of this study is to examine whether it is possible to increase the amount of walking that people do during their journeys to and from work. The research will also examine whether it is a good use of money to try to increase walking in this way.

Who can participate?
84 workplaces in Bath, South Gloucestershire and Swansea will be recruited through the Chambers of Commerce. Employees who do not always walk or cycle to work already will be asked if they would like to take part in the study.

What does the study involve?
In 42 randomly-allocated workplaces, volunteers (Walk to Work promoters) are recruited and trained to encourage other employees to walk during the journey to and from work. People who live close to the workplaces are encouraged to walk all of the way. Those living further away are encouraged to use public transport which usually involves more walking than driving a private car, or to park their cars further away and walk the rest of the journey. People who take part are given Walk to Work booklets and pedometers. They are helped to work out safe walking routes and encouraged to set goals for walking to work. Extra encouragement is provided through four contacts from the Walk to Work promoter over the following 10 weeks. This is in person, by email or by telephone, whichever is better for the workplaces and the employees. The other 42 workplaces carry on as usual so that physical activity and travel mode can be compared between those people in workplaces that receive the intervention and those who do not. Everyone taking part in the study are asked to wear accelerometers (a small monitor, worn on a belt around the waist, to measure levels of physical activity) for 7 days at the beginning of the study and again a year later. They are also be asked to wear GPS monitors to check how much of their activity takes place on the journey to and from work; and to complete travel diaries and questionnaires about their journeys to work. Some of the employees, employers and Walk to Work promoters are interviewed about their views and experiences of the study and the factors which make it possible for some people to walk to work while others do not. To find out if it is a good use of money to try to increase walking in this way, the costs need to be compared with the benefits. To do this, the time spent training the Walk to Work promoters and encouraging people to walk to work is recorded, as well as the costs of the booklets and other resources such as pedometers. Absentee rates are collected from employers; and participants' journey time, travel costs of getting to and from work, and health service use are recorded using travel diaries and questionnaires.

What are the possible benefits and risks of participating?
Physical activity reduces the risks of chronic diseases including type 2 diabetes, coronary heart disease and some cancers. This is a low-risk intervention. However, we will be mindful of the potential for harm in terms of personal safety of walkers. Participating workplaces and Walk to Work promoters will have the contact details of the Principal Investigator, Dr Suzanne Audrey, to report adverse incidents which will be recorded and kept on file. If adverse events are attributable to the intervention, relevant participants will be informed immediately, e.g. other employees taking a similar route crossing a dangerous road or walking through dimly lit areas with high rates of street crime. It is also possible that people with low activity and no history of walking will suffer from initial muscle stiffness. In most cases this would be mild and is a normal consequence of increased physical activity. However, participants will be given information about symptoms which may require medical attention and temporary or permanent cessation of walking to work: for example, where underlying joint weakness is exposed. Such incidents will be recorded and monitored throughout the study.

Where is the study run from?
1. University of Bristol (UK)
2. University of Bath (UK)
3. Swansea University (UK)

When is the study starting and how long is it expected to run for?
November 2014 to July 2017

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Dr Suzanne Audrey
suzanne.audrey@bristol.ac.uk

Trial website

Contact information

Type

Scientific

Primary contact

Dr Suzanne Audrey

ORCID ID

Contact details

School for Social and Community Medicine
Canynge Hall
Whatley Road
Bristol
BS8 2PS
United Kingdom
+44 (0)117 928 7273
suzanne.audrey@bristol.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

NIHR-PHR: Project 13/117/01

Study information

Scientific title

The effectiveness and cost-effectiveness of an employer-led intervention to increase walking during the daily commute: a cluster randomised controlled trial

Acronym

Study hypothesis

The overall aim of the research is to examine the effectiveness and cost-effectiveness of an employer-led scheme to increase walking during the daily commute. The objectives are:
1. To recruit and train workplace-based Walk to Work promoters
2. To provide evidence of: participating employees’ moderate to vigorous physical activity (MVPA); participating employees’ overall levels of physical activity (cpm); modal shift (number of days, over the previous five working days, when walking was the major mode of travel to/from work); temporal pattern of physical activity (to identify when activity has increased and whether there is a compensatory decrease in activity at other times); physical activity associated with the journey to and from work
3. To assess intervention costs to participating employers and employees
4. To provide evidence on the cost and economic benefits of the intervention to employers, employees and society (commuting costs, health service use, presenteeism, absenteeism, capabilities)
5. To explore with employers and employees the barriers to, and facilitators of, employer-led schemes to promote walking during the daily commute
6. To explore any social patterning in increased walking particularly in relation to socio-economic status, age and gender

More details can be found here: http://www.nets.nihr.ac.uk/projects/phr/1311701

Ethics approval

University of Bristol Faculty of Medicine and Dentistry Committee for Research Ethics, 20/04/2014, application number: 131422 (6402)

Study design

Cluster randomised controlled trial

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Trial setting

Other

Trial type

Other

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Physical activity

Intervention

There are three main stages of the intervention:
1. Workplace ‘Walk to Work promoters’ will be identified (volunteers, or nominated by participating employers, with an interest in walking and the capacity, within their usual role in the workplace, to promote walking amongst their colleagues). The Walk to Work promoters will be trained (at a group external event or on site, as appropriate to the needs of the workplace) by expert members of the research team about the health, social, economic and environmental benefits of walking during the daily commute and how to promote increased walking either by walking the entire route (mainly those within two miles of the workplace) or mixing walking with public transport or ‘park and walk’. They will be given resource packs and trained to access relevant websites and toolkits.
2. Participating employees will be contacted by the Walk to Work promoter and will be given a Walk to Work pack including a booklet and pedometer. The benefits of increased walking will be discussed; barriers and solutions discussed, and safe, feasible routes identified. Goals for incorporating walking into the journey to and from work will be set.
3. Further encouragement will be provided through four contacts from the Walk to Work promoter over the following 10 weeks (face-to-face, email or telephone as appropriate). During this time the Walk to Work promoters will also be prompted and encouraged in their role by four email/telephone contacts.

Workplaces in the control arm will continue as usual.

Intervention type

Behavioural

Phase

Drug names

Primary outcome measures

Daily minutes of moderate to vigorous physical activity (MVPA), measured using accelerometers at baseline and one-year follow-up

Secondary outcome measures

Physical activity:
1. Overall levels of physical activity (cpm), measured using accelerometers
2. Daily minutes of sedentary time
3. Modal shift (number of days, over the previous five working days, when walking was the major mode of travel to/from work)

Process outcomes:
1. Facilitators and barriers to workplace/employer participation in Walk to Work interventions
2. Facilitators and barriers to employees walking during the daily commute
3. Physical activity/MVPA due to walking during the journey to/from work

Economic evaluation outcomes:
1. Costs to employers, employees and the public sector of implementing the Walk to Work scheme
2. Consequences for the employer; absenteeism/presenteeism
3. Consequences for employees; commuting costs and wellbeing
4. Consequences for the public sector; health service use

Overall trial start date

01/11/2014

Overall trial end date

31/07/2017

Reason abandoned

Eligibility

Participant inclusion criteria

Employees:
1. Of any age and gender
2. In small, medium and large workplaces
2. In Bath, Swansea and South Gloucestershire

Participant type

Healthy volunteer

Age group

Adult

Gender

Both

Target number of participants

672

Participant exclusion criteria

1. Employees who always walk or cycle to work
2. Employees who are disabled in relation to walking to work, and employees whose job involves regular driving throughout the day (for example, delivery drivers or sales representatives who set off from home in the work vehicle)
3. Organisations with little direct communication between senior management and employees are not suited to this intervention (unless there is a local supervisor/manager with the authority to agree the study activities) because of the need for employer support for recruitment of participants and Walk to Work promoters
4. Workplaces with a large proportion of staff on short-term or zero-hours contracts are not suited because of the need for a one-year follow-up data collection
5. Employees who are retiring before the one-year follow-up data collection
6. Workplaces with firm plans to significantly downsize or relocate during the study period

Recruitment start date

01/03/2015

Recruitment end date

30/06/2016

Locations

Countries of recruitment

United Kingdom

Trial participating centre

University of Bristol
School of Social and Community Medicine
Bristol
BS8 2PS
United Kingdom

Trial participating centre

University of Bath
Bath
BA2 7AY
United Kingdom

Trial participating centre

Swansea University
Swansea
SA2 8PP
United Kingdom

Sponsor information

Organisation

University of Bristol

Sponsor details

Senate House
Tyndall Avenue
Bristol
BS8 1TH
United Kingdom

Sponsor type

University/education

Website

Funders

Funder type

Government

Funder name

National Institute for Health Research

Alternative name(s)

NIHR

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Participant level data

Not expected to be available

Results - basic reporting

Publication summary

2015 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/25778164

Publication citations

Additional files

Editorial Notes